Search Results - "Oldenhuis, C."

Prognostic versus predictive value of biomarkers in oncology by Oldenhuis, C.N.A.M, Oosting, S.F, Gietema, J.A, de Vries, E.G.E

“…Abstract Numerous options are currently available for tumour typing. This has raised intense interest in the elucidation of prognostic and predictive markers…”
Get full text

Targeting TRAIL death receptors by Oldenhuis, CNAM, Stegehuis, JH, Walenkamp, AME, de Jong, S, de Vries, EGE

“…The natural occurring tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis following binding to the two TRAIL death receptors…”
Get full text

370 A phase Ib study of escalating doses of Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitor Tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors by Eskens, F, Oldenhuis, C, Bhargava, P, Loos, W, Esteves, B, van Doorn, L, Cotreau, M, Dillon, R, Gietema, J, de Vries, E

Get full text

A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors by Eskens, F., Oldenhuis, C. N., Bhargava, P., Loos, W., Esteves, B., van Doorn, L., Cotreau, M. M., Dhillon, R., Gietema, J. A., De Vries, E.

“…Abstract only 549 Background: Tivozanib (AV-951), a highly potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors…”
Get full text

Development of radiolabeled mapatumumab and imaging in solid tumor patients who are treated with gemcitabine, cisplatin, and mapatumumab by Oldenhuis, C., Dijkers, E. C., Duiker, E. W., Fox, N. L., Klein, J. L., Gietema, J. A., Brouwers, A. H., Lub-de Hooge, M. N., de Vries, E. G.

“…Abstract only e14521 Background: Mapatumumab is a fully human agonistic monoclonal antibody (mAb) to the tumor necrosis factor-related apoptosis-inducing…”
Get full text

Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors by Sharma, S., de Vries, E. G., Infante, J. R., Oldenhuis, C., Chiang, L., Bilic, S., Goldbrunner, M., Scott, J. W., Burris, H. A.

“…Abstract only…”
Get full text

A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin by Oldenhuis, C., Mom, C., Sleijfer, S., Gietema, J. A., Fox, N. L., Corey, A., Eskens, F., Loos, W., de Vries, E. G., Verweij, J.

“…Abstract only…”
Get full text